Эффективность бевацизумаба при прогрессирующей глиобластоме. Собственные данные

No standard of care has been established for patients with progressive glioblastoma (rGB). Previous studies suggested that bevacizumab (BEV) is safe and produces responses that result in a decreased use of glucocorticoids and increased progression-free survival (PFS) with an unclear effect on overall survival (OS). Crossover to BEV in the control arm is the possible reason why the advantage of BEV has not been proven in Phase III trials. We present our own retrospective data on the effectiveness of the use of BEV in the rGB. Special attention was paid to the analysis of the consequences of BEV discontinuation in the absence of tumor progression and the benefit of continuing or resuming BEV at relapse.